PL417178A1 - Hydrat A aripiprazolu i sposób jego wytwarzania - Google Patents

Hydrat A aripiprazolu i sposób jego wytwarzania

Info

Publication number
PL417178A1
PL417178A1 PL417178A PL41717802A PL417178A1 PL 417178 A1 PL417178 A1 PL 417178A1 PL 417178 A PL417178 A PL 417178A PL 41717802 A PL41717802 A PL 41717802A PL 417178 A1 PL417178 A1 PL 417178A1
Authority
PL
Poland
Prior art keywords
producing
aripiprazole hydrate
aripiprazole
hydrate
preparation
Prior art date
Application number
PL417178A
Other languages
English (en)
Other versions
PL230869B1 (pl
Inventor
Takuji Bando
Satoshi Aoki
Junichi Kawasaki
Makoto Ishigami
Youichi Taniguchi
Tsuyoshi Yabuuchi
Kiyoshi Fujimoto
Yoshihiro Nishioka
Noriyuki Kobayashi
Tsutomu Fujimura
Masanori Takahashi
Kaoru Abe
Tomonori Nakagawa
Koichi Shinhama
Naoto Utsumi
Michiaki Tominaga
Yoshihiro Oi
Shohei Yamada
Kenji Tomikawa
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36049773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL417178(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 2379005 external-priority patent/CA2379005A1/en
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Priority claimed from PCT/JP2002/009858 external-priority patent/WO2003026659A1/en
Publication of PL417178A1 publication Critical patent/PL417178A1/pl
Publication of PL230869B1 publication Critical patent/PL230869B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Przedmiotem wynalazku jest hydrat A aripiprazolu oraz sposób jego wytwarzania.
PL417178A 2001-09-25 2002-09-25 Hydrat A aripiprazolu i sposób jego wytwarzania PL230869B1 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2001-290645 2001-09-25
JP2001290645 2001-09-25
JP2001348276 2001-11-14
JP2001-348276 2001-11-14
CA2379005 2002-03-27
CA 2379005 CA2379005A1 (en) 2001-09-25 2002-03-27 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
PCT/JP2002/009858 WO2003026659A1 (en) 2001-09-25 2002-09-25 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Publications (2)

Publication Number Publication Date
PL417178A1 true PL417178A1 (pl) 2016-07-04
PL230869B1 PL230869B1 (pl) 2018-12-31

Family

ID=36049773

Family Applications (7)

Application Number Title Priority Date Filing Date
PL393608A PL219564B1 (pl) 2001-09-25 2002-09-25 Kryształy E bezwodnego aripiprazolu, sposób ich wytwarzania, kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny zawierające kryształy E bezwodnego aripiprazolu
PL393596A PL393596A1 (pl) 2001-09-25 2002-09-25 Kryształy G bezwodnego aripiprazolu i sposób ich wytwarzania oraz kompozycja farmaceutyczna je zawierająca, farmaceutyczny stały preparat doustny i sposób jego wytwarzania oraz sposób wytwarzania granulek
PL417178A PL230869B1 (pl) 2001-09-25 2002-09-25 Hydrat A aripiprazolu i sposób jego wytwarzania
PL393603A PL221536B1 (pl) 2001-09-25 2002-09-25 Kryształy C bezwodnego aripiprazolu i sposób ich wytwarzania oraz zawierające je kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny
PL393598A PL221521B1 (pl) 2001-09-25 2002-09-25 Kryształy F bezwodnego aripiprazolu i sposób ich wytwarzania oraz zawierające je kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny
PL393601A PL219565B1 (pl) 2001-09-25 2002-09-25 Kryształy D bezwodnego aripiprazolu, sposób ich wytwarzania, kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny zawierające kryształy D bezwodnego aripiprazolu
PL393607A PL393607A1 (pl) 2001-09-25 2002-09-25 Sposób wytwarzania granulek farmaceutycznego stałego preparat doustnego i sposób wytwarzania farmaceutycznego stałego preparatu doustnego oraz farmaceutyczny stały preparat doustny

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL393608A PL219564B1 (pl) 2001-09-25 2002-09-25 Kryształy E bezwodnego aripiprazolu, sposób ich wytwarzania, kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny zawierające kryształy E bezwodnego aripiprazolu
PL393596A PL393596A1 (pl) 2001-09-25 2002-09-25 Kryształy G bezwodnego aripiprazolu i sposób ich wytwarzania oraz kompozycja farmaceutyczna je zawierająca, farmaceutyczny stały preparat doustny i sposób jego wytwarzania oraz sposób wytwarzania granulek

Family Applications After (4)

Application Number Title Priority Date Filing Date
PL393603A PL221536B1 (pl) 2001-09-25 2002-09-25 Kryształy C bezwodnego aripiprazolu i sposób ich wytwarzania oraz zawierające je kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny
PL393598A PL221521B1 (pl) 2001-09-25 2002-09-25 Kryształy F bezwodnego aripiprazolu i sposób ich wytwarzania oraz zawierające je kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny
PL393601A PL219565B1 (pl) 2001-09-25 2002-09-25 Kryształy D bezwodnego aripiprazolu, sposób ich wytwarzania, kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny zawierające kryształy D bezwodnego aripiprazolu
PL393607A PL393607A1 (pl) 2001-09-25 2002-09-25 Sposób wytwarzania granulek farmaceutycznego stałego preparat doustnego i sposób wytwarzania farmaceutycznego stałego preparatu doustnego oraz farmaceutyczny stały preparat doustny

Country Status (21)

Country Link
EP (1) EP3081216A1 (pl)
KR (2) KR100530731B1 (pl)
CN (12) CN105832677A (pl)
AR (3) AR073111A2 (pl)
CA (1) CA2713466C (pl)
CL (1) CL2010000405A1 (pl)
CY (4) CY1110208T1 (pl)
DK (1) DK1925308T3 (pl)
ES (1) ES2596354T3 (pl)
HK (5) HK1203059A1 (pl)
IL (3) IL204707A (pl)
LT (1) LT1925308T (pl)
MY (1) MY138669A (pl)
NO (1) NO337844B1 (pl)
PE (1) PE20030445A1 (pl)
PH (1) PH12014500782A1 (pl)
PL (7) PL219564B1 (pl)
PT (1) PT1925308T (pl)
RU (1) RU2279429C2 (pl)
SI (1) SI1927357T1 (pl)
TW (2) TWI332839B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931784B1 (ko) * 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR102128883B1 (ko) * 2019-10-02 2020-07-01 (주)삼화바이오팜 고순도 아리피프라졸의 신규 결정형 및 이의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3638447B2 (ja) * 1998-09-10 2005-04-13 積水ハウス株式会社 笠木取付金具および笠木取付構造
GB9930061D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Quinolone compounds for use in treating viral infections
ATE362926T1 (de) * 2000-01-20 2007-06-15 Eisai R&D Man Co Ltd Stickstoffhaltige cyclische verbindungen und sie enthaltende pharmazeutische zubereitungen
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
JP4197088B2 (ja) 2000-06-05 2008-12-17 電気化学工業株式会社 低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法
JP2002193915A (ja) * 2000-12-28 2002-07-10 Otsuka Pharmaceut Co Ltd ベンゼンスルフォナート化合物

Also Published As

Publication number Publication date
MY138669A (en) 2009-07-31
RU2279429C2 (ru) 2006-07-10
NO337844B1 (no) 2016-06-27
HK1136958A1 (en) 2010-07-16
PL393608A1 (pl) 2011-03-14
NO20141193L (no) 2003-01-17
CL2010000405A1 (es) 2010-10-15
CN103751093A (zh) 2014-04-30
IL204707A0 (en) 2010-11-30
HK1210468A1 (en) 2016-04-22
IL204707A (en) 2016-06-30
IL225902A0 (en) 2013-06-27
HK1215397A1 (zh) 2016-08-26
AR073111A2 (es) 2010-10-13
CN105832677A (zh) 2016-08-10
TW200942238A (en) 2009-10-16
PL221536B1 (pl) 2016-04-29
CN104945321A (zh) 2015-09-30
KR20030060871A (ko) 2003-07-16
CN103288727A (zh) 2013-09-11
CN103288727B (zh) 2016-04-27
CN103755632B (zh) 2016-06-29
HK1129891A1 (en) 2009-12-11
KR100530731B1 (ko) 2005-11-23
TWI318572B (en) 2009-12-21
PL230869B1 (pl) 2018-12-31
HK1196128A1 (zh) 2014-12-05
HK1187048A1 (zh) 2014-03-28
PH12014500782A1 (en) 2018-09-10
PL219565B1 (pl) 2015-05-29
HK1136961A1 (en) 2010-07-16
TWI332839B (en) 2010-11-11
CN104306374A (zh) 2015-01-28
RU2004126636A (ru) 2006-02-10
CA2713466A1 (en) 2003-04-03
ES2596354T3 (es) 2017-01-09
PL221521B1 (pl) 2016-04-29
CN104306337A (zh) 2015-01-28
HK1203060A1 (en) 2015-10-16
HK1223043A1 (zh) 2017-07-21
CN105267151A (zh) 2016-01-27
PL219564B1 (pl) 2015-05-29
CN102579446A (zh) 2012-07-18
CN103751118A (zh) 2014-04-30
PL393601A1 (pl) 2011-04-26
HK1129889A1 (en) 2009-12-11
AR087544A2 (es) 2014-04-03
KR100490222B1 (ko) 2005-05-18
HK1136960A1 (en) 2010-07-16
CN103755632A (zh) 2014-04-30
PL393596A1 (pl) 2011-04-26
LT1925308T (lt) 2016-11-10
SI1927357T1 (sl) 2010-09-30
PE20030445A1 (es) 2003-07-26
DK1925308T3 (en) 2016-12-12
PL393598A1 (pl) 2011-04-26
CN103751119A (zh) 2014-04-30
PL393603A1 (pl) 2011-04-26
HK1092808A1 (en) 2007-02-16
PT1925308T (pt) 2016-10-24
CY1110244T1 (el) 2015-01-14
CY1110208T1 (el) 2015-01-14
CA2713466C (en) 2012-01-03
HK1136959A1 (en) 2010-07-16
IL234770A0 (en) 2014-11-30
KR20040053372A (ko) 2004-06-23
EP3081216A1 (en) 2016-10-19
CN103191118A (zh) 2013-07-10
AR077635A2 (es) 2011-09-14
CY1110070T1 (el) 2015-01-14
CY1110212T1 (el) 2015-01-14
PL393607A1 (pl) 2011-03-14
HK1203059A1 (en) 2015-10-16

Similar Documents

Publication Publication Date Title
ATE453648T1 (de) Verfahren zur herstellung von hexahydrofuroc2,3- büfuran-3-ol
DE50202715D1 (de) Verfahren zur herstellung von hochreinen, tris-ortho-metallierten organo-iridium-verbindungen
BG105009A (en) Method for producing 4-carboxyamino-2-substituted 1,2,3,4-tetrahydroquinoline
DE50109023D1 (de) Vorrichtung zur Herstellung von Wellrohren
HUP0200589A3 (en) Soot, process for producing it and use
PL371127A1 (pl) Pochodne 6-amino-morfinianu, metody ich otrzymywania oraz ich zastosowania
BG111461A (en) TECHNICAL METHOD FOR OBTAINING TROPENOL
DE602005015174D1 (de) Verfahren zur herstellung von montelukast-natrium
ZA200203994B (en) Method of fuel production from Fischer-Tropsch process.
EP1383865A4 (en) METHOD FOR THE PRODUCTION OF TYROSIN, Cinnamic Acid and Para-Hydroxycinnamic Acid
GB0504952D0 (en) Process for producing arylamine
ATE506351T1 (de) Verfahren zur herstellung von 10,11-dihydro-10- oxo-5h-dibenzoäb,füazepin-5-carboxamid
MXPA03006154A (es) Metodo de fabricacion de vacuna combinada.
DE60219188D1 (de) Verfahren zur herstellung von olefinen.
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
ATE374757T1 (de) Verfahren zur herstellung von (1,4,5)- oxadiazepinderivaten
PL417178A1 (pl) Hydrat A aripiprazolu i sposób jego wytwarzania
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
ATE387425T1 (de) Verfahren zur herstellung von bicalutamid
MX234329B (es) Metodo para producir n-fosfonometilglicina.
SG146645A1 (en) Process for the synthesis of 6-amino-4-(3-chloro-4fluoro-phenylamino)-7- ethoxy-quinoline-3-carbonitrile
MXPA03008119A (es) Metodo para la produccion de 2,6-dialquilmorfolinas n-sustituidas.
DE50103009D1 (de) Verfahren zur herstellung von 2-alkyl-3-chlorphenolen
MXPA02003042A (es) Proceso para prevenir formacion de incrustaciones.
MXPA03009684A (es) Procedimiento para la preparacion de 2-(5-(4-fluorofenil)-3- piridilmetilaminometil)-cromano.